Clinical trials: Opioid Agonist Treatment
Opioid Use Disorder, Opioid Withdrawal
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
A major challenge to seeking treatment for opioid use disorder (OUD) is the withdrawal symptoms associated with cessation of opioid use.
- Trial name
- NCT05712707
- Testing
- BXCL501 (180 micrograms), BXCL501 (240 micrograms), Lofexidine (Positive Control)
- Where
- 4 sites in United States
- Volunteers
- 160 people
- Sponsor
- New York State Psychiatric Institute
Acute Pain
Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction
The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.
- Trial name
- NCT00993863
- Testing
- ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Opioid-Related Disorders, Heroin Dependence
Study of Computer-Based Treatment for Drug Dependence
The purpose of this study is to evaluate the whether an automated telephone-based system is useful and helpful for opioid dependent patients receiving buprenorphine in primary care.
- Trial name
- RLSS (NCT01315184)
- Testing
- Recovery Line Support System
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Yale University
Opioid-Related Disorders, HIV
Neurocognitive Effects of Opiate Agonist Treatment
The purpose of this study is to (1) compare the effects of buprenorphine and methadone, two types of opioid addiction treatment, on the ability to think and reason among people addicted to opiates, and who are either HIV negative…
- Conditions
- Opioid-Related Disorders, HIV, HIV Infections
- Trial name
- NEO (NCT01733693)
- Testing
- Buprenorphine, Methadone
- Where
- 2 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Opioid Dependence, on Agonist Therapy
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent…
- Trial name
- NCT01903005
- Testing
- Higher bioavailability BNX sublingual tablets
- Where
- 28 sites in United States
- Volunteers
- 668 people
- Sponsor
- Orexo AB
Cocaine Use Disorder
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
In The Netherlands, each year, about 15 thousand people come into treatment because of problems with cocaine use. There is no approved medication for treatment of cocaine addiction and the psychosocial treatment patients receive…
- Trial name
- NCT05529927
- Testing
- Sustained-release Dexamphetamine
- Where
- Netherlands
- Volunteers
- 204 people
- Sponsor
- Parnassia Addiction Research Centre
Substance Use Disorders
Benzodiazepine Discontinuation in Opioid Agonist Therapy
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy who currently use benzodiazepines.
- Trial name
- BZD-OAT (NCT04109118)
- Testing
- Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), BZD discontinuation protocol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston Medical Center
Substance Use Disorders
Distress Tolerance for Benzodiazepine Discontinuation
The proposed study is a clinical trial, designed to pilot test a Distress Tolerance-Benzodiazepine Discontinuation (DT-BD) intervention for patients on opioid agonist therapy (OAT) who currently use benzodiazepines versus a…
- Trial name
- DT-BD (NCT05250570)
- Testing
- Distress Tolerance - Benzodiazepine Discontinuation (DT-BD), Relaxation Therapy
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Pittsburgh
Post Traumatic Stress Disorder, Opioid-use Disorder
Prolonged Exposure Therapy for PTSD and Opioid Use Disorder
Among patients with opioid use disorder (OUD), 90% report lifetime trauma exposure and 33% meet criteria for posttraumatic stress disorder (PTSD).
- Trial name
- NCT04104022
- Testing
- Prolonged Exposure Therapy, Attendance-based monetary incentives
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- University of Vermont
Hepatitis C, Chronic, Opioid Dependence, on Agonist Therapy
Integrated Treatment of Hepatitis C Virus Infection
INTRO-HCV is a multicentre randomised controlled clinical trial that will compare the efficacy of integrated treatment of chronic hepatitis C virus infection (HCV) within medically assisted rehabilitation (MAR) clinics providing…
- Trial name
- INTRO-HCV (NCT03155906)
- Testing
- Health care delivery
- Where
- 2 sites in Norway
- Volunteers
- 298 people
- Sponsor
- Haukeland University Hospital
Opioid-use Disorder, Opioid Withdrawal
Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions
This study will compare medically-supervised withdrawal (MSW, 'detoxification') to opioid agonist treatment (OAT, 'maintenance') with buprenorphine for pregnant women with opioid use disorder in terms of maternal, fetal, and…
- Conditions
- Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
- Trial name
- MOTHER DYAD (NCT04049799)
- Testing
- Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
- Where
- 4 sites in United States
- Volunteers
- 88 people
- Sponsor
- University of Vermont